These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 34504076)

  • 21. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
    Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
    Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
    Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
    SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
    Lito P; Solomon M; Li LS; Hansen R; Rosen N
    Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function.
    Kattan WE; Chen W; Ma X; Lan TH; van der Hoeven D; van der Hoeven R; Hancock JF
    Life Sci Alliance; 2019 Oct; 2(5):. PubMed ID: 31451509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
    Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
    Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
    Kirschner T; Müller MP; Rauh D
    J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
    Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a Covalent Inhibitor of KRAS
    Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
    J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels.
    Bojjireddy N; Botyanszki J; Hammond G; Creech D; Peterson R; Kemp DC; Snead M; Brown R; Morrison A; Wilson S; Harrison S; Moore C; Balla T
    J Biol Chem; 2014 Feb; 289(9):6120-32. PubMed ID: 24415756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
    Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
    Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
    Maroni G; Bassal MA; Krishnan I; Fhu CW; Savova V; Zilionis R; Maymi VA; Pandell N; Csizmadia E; Zhang J; Storti B; Castaño J; Panella R; Li J; Gustafson CE; Fox S; Levy RD; Meyerovitz CV; Tramontozzi PJ; Vermilya K; De Rienzo A; Crucitta S; Bassères DS; Weetall M; Branstrom A; Giorgetti A; Ciampi R; Del Re M; Danesi R; Bizzarri R; Yang H; Kocher O; Klein AM; Welner RS; Bueno R; Magli MC; Clohessy JG; Ali A; Tenen DG; Levantini E
    Commun Biol; 2021 Apr; 4(1):370. PubMed ID: 33854168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
    Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
    Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
    Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.